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The trimeric envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) mediates virus entry into host
cells. CD4 engagement with the gp120 exterior envelope glycoprotein subunit represents the first step during HIV-1 entry.
CD4-induced conformational changes in the gp120 inner domain involve three potentially flexible topological layers (lay-
ers 1, 2, and 3). Structural rearrangements between layer 1 and layer 2 have been shown to facilitate the transition of the
envelope glycoprotein trimer from the unliganded to the CD4-bound state and to stabilize gp120-CD4 interaction. How-
ever, our understanding of CD4-induced conformational changes in the gp120 inner domain remains incomplete. Here, we
report that a highly conserved element of the gp120 inner domain, layer 3, plays a pivot-like role in these allosteric
changes. In the unliganded state, layer 3 modulates the association of gp120 with the Env trimer, probably by influencing
the relationship of the gp120 inner and outer domains. Importantly, layer 3 governs the efficiency of the initial gp120 in-
teraction with CD4, a function that can also be fulfilled by filling the Phe43 cavity. This work defines the functional impor-
tance of layer 3 and completes a picture detailing the role of the gp120 inner domain in CD4-induced conformational tran-
sitions in the HIV-1 Env trimer.
Human immunodeficiency virus type 1 (HIV-1) entry, medi-ated by the viral envelope glycoproteins (Env), is a central
process of the viral infectious cycle. The HIV-1 Env trimer is the
only virus-specific antigen present on the virion surface; therefore,
it constitutes the sole target for HIV-1-neutralizing antibodies.
ThematureHIV-1 Env trimer is derived fromproteolytic cleavage
of a trimeric gp160 precursor (1, 2) and is composed of exterior
gp120 and transmembrane gp41 subunits. The gp120 exterior
subunit is retained on the trimer via labile, noncovalent interac-
tions with the gp41 ectodomain (3–5). The gp120 glycoprotein is
responsible for interactions with the initial receptor, CD4 (6, 7),
upon which conformational changes expose the binding site for
the chemokine coreceptors (CCR5 and CXCR4) (8–12). CD4
binding induces conformational changes within the HIV-1 Env
trimer that result in the transition of the gp41 ectodomain into
prehairpin intermediates (13, 14). Upon chemokine receptor
binding, heptad repeat regions HR1 and HR2 form a six-helix
bundle, promoting fusion of the viral and target cell membranes
(15, 16).
As the major viral determinant recognized by the neutralizing
antibody response, the HIV-1 Env trimer represents a likely can-
didate for a vaccine immunogen. Binding of an antibody to any
part of the functional HIV-1 Env spike has the potential to block
HIV infection (17, 18). However, vaccination efforts with both
monomeric and trimeric Env constructs in soluble or recombi-
nant forms elicited responses that wereminimally effective against
themajority of primaryHIV-1 isolates (19–21). Nonetheless, par-
tial efficacy observed in the RV144 vaccine trial (22) renewed in-
terest in HIV-1 Env as an immunogen candidate. However, to
engineer an HIV-1 Env immunogen capable of eliciting broadly
neutralizing antibodies, it may be important to understand better
the different conformations sampled by the native Env trimers.
Detailed structural information has been obtained by X-ray
crystallography for monomeric HIV-1 gp120 core in complex
with stabilizing ligands such as soluble CD4 (sCD4) and/or anti-
bodies (Abs) (23–27). However, crystallization has required
deglycosylation and truncation of variable regions, removing
structural constraints that apparently maintain the conforma-
tional integrity of the unliganded Env trimer (28). These studies
have led to the hypothesis that, upon CD4 binding, the outer
domain of gp120 does not change conformation, whereas three
topological layers in the gp120 inner domain undergo conforma-
tional shifts (27). Until recently, other approaches such as cryo-
electron tomography of virion Env spikes and cryo-electron mi-
croscopy (cryo-EM) analysis of purified Env variants have only
yielded density maps at 18- to 30-Å resolution (29–34), insuffi-
cient for assessing detailed structural variations. However, the
structure of the fully glycosylated, membrane-bound HIV-1 Env
trimer precursor in its unliganded state, including the complete
exterior and transmembrane regions, has been recently solved to
11-Å resolution by cryo-EM (35). This structure revealed the
architectural organization of the gp120 and gp41 subunits and,
consistent with our previous mutagenic and functional studies
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(3), the existence of conformational differences between the unli-
ganded and CD4-bound states in the Env trimer, particularly in
the inner domain (35). Whereas the role of layers 1 and 2 in the
conformational transition from the unbound to the CD4-bound
conformation has been previously reported (3), a role for the
functionally undercharacterized layer 3 of the HIV-1 gp120 inner
domain (8 strand and 5 of the CD4-bound gp120, comprising
residues 247 to 254 and 476 to 483, respectively) has not yet been
addressed.Here, we characterize the importance of this element to
Env integrity and to the process of viral entry and investigate its
role in the transition to the CD4-bound conformation.
MATERIALS AND METHODS
Cell lines. 293T human embryonic kidney, Cf2Th canine thymocytes
(American Type Culture Collection) and TZM-bl cell lines (NIH AIDS
Research and Reference Reagent Program) were grown at 37°C and 5%
CO2 in Dulbecco’s modified Eagle’s medium (Invitrogen) containing
10% fetal bovine serum (Sigma) and 100 g/ml of penicillin-streptomy-
cin (Mediatech). Cf2Th cells stably expressing human CD4 and CCR5
(Cf2Th-CD4-CCR5) (36) were grown in medium supplemented with 0.4
mg/ml of G418 (Invitrogen) and 0.15 mg/ml of hygromycin B (Roche
Diagnostics). Cf2Th-CCR5 cells were grown in medium supplemented
with 0.4 mg/ml of G418 (Invitrogen). The TZM-bl cell line is a HeLa cell
line stably expressing high levels of CD4 and CCR5 and possessing an
integrated copy of the luciferase gene under the control of the HIV-1 long
terminal repeat (37).
Site-directed mutagenesis. Mutations were introduced individually
or in combination into the previously described pSVIIIenv vector ex-
pressing the HIV-1YU2 envelope glycoproteins (3). Site-directed mu-
tagenesis was performed using a QuikChange II XL site-directed
mutagenesis protocol (Stratagene). For cell-based enzyme-linked immu-
nosorbent assays (ELISAs), a stop codon was introduced to replace the
codon for Gly711, truncating the cytoplasmic tail (CT) and enhancing
cell surface expression of selected HIV-1YU2 envelope glycoproteins. The
presence of the desired mutations was determined by automated DNA
sequencing. The numbering of the HIV-1 envelope glycoprotein amino
acid residues is based on that of the prototypic HXBc2 strain of HIV-1,
where position 1 is the initial methionine (38).
Immunoprecipitation of envelope glycoproteins. For pulse-labeling
experiments, 3 105 293T cells were cotransfected by the calcium phos-
phate method with pLTR-Tat and the pSVIIIenv vector expressing the
HIV-1YU2 envelope glycoproteins. One day after transfection, cells were
metabolically labeled for 16 h with 100 Ci/ml [35S]methionine-cysteine
([35S] Protein Labeling Mix; Perkin-Elmer) in Dulbecco’s modified
Eagle’s medium lacking methionine and cysteine and supplemented with
5% dialyzed fetal bovine serum. Cells were subsequently lysed in radio-
immunoprecipitation assay (RIPA) buffer (140 mM NaCl, 8 mM
Na2HPO4, 2 mM NaH2PO4, 1% NP-40, 0.05% sodium dodecyl sulfate
[SDS]). Precipitation of radiolabeled HIV-1YU2 envelope glycoproteins
from cell lysates or medium was performed with a mixture of sera from
HIV-1-infected individuals. Alternatively, the radiolabeled gp120 enve-
lope glycoprotein in the medium was precipitated with various amounts
of anti-gp120monoclonal antibodies (MAbs) or the recombinant CD4-Ig
protein for 1 h at 37°C in the presence of 50 l of 10% protein A-Sephar-
ose (American BioSciences).
Processing and association indices were determined by precipitation
of radiolabeled cell lysates and supernatants with mixtures of sera from
HIV-1-infected individuals. The association index is a measure of the
ability of the mutant gp120 molecule to remain associated with the Env
trimer complex on the expressing cell, relative to that of thewild-type (wt)
Env trimers. The association index is calculated as follows: association
index  ([mutant gp120]cell  [wild-type gp120]supernatant)/([mutant
gp120]supernatant [wild-type gp120]cell). The processing index is a mea-
sure of the conversion of the mutant gp160 Env precursor to mature
gp120, relative to that of the wild-type Env trimers. The processing index
was calculated by the following formula: processing index  ([total
gp120]mutant [gp160]wild type)/([gp160]mutant [total gp120]wild type).
Cell-based ELISA.Detection of trimeric Env on the surface of COS-1
cells was performed by cell-based ELISA, as described previously (39).
Briefly, COS-1 cells were seeded in 96-well plates (2 104 cells per well)
and transfected the next day with 0.15 g of the pSVIIIenv plasmid ex-
pressing the envelope glycoproteins and 0.01 g of a Tat-expressing plas-
mid per well, using the standard polyethylenimine (PEI) (Polyscience
Inc., PA) transfection method. Two days later, cells were washed twice
with blocking buffer (10 mg/ml nonfat dry milk, 1.8 mM CaCl2, 1 mM
MgCl2, 25 mMTris, pH 7.5, and 140 mMNaCl) and then incubated for 1
h at room temperature with a 1/2,000 dilution of heat-inactivated serum
from HIV-1-infected individuals, 20 nM CD4-Ig (a fusion protein in
which the N-terminal two domains of CD4 are linked to the Fc compo-
nent of immunoglobulin G [40]), or anti-HIV-1 Env monoclonal anti-
bodies. All ligands were diluted in blocking buffer. In some instances, 20
nM sCD4 or CD4-Ig was added in blocking buffer for 1 h at room tem-
perature (RT) prior to the addition of 20 nM CD4-induced (CD4i) anti-
bodies (17b and 48d) for another hour. A horseradish peroxidase (HRP)-
conjugated antibody specific for the Fc region of human IgG (Pierce) was
then incubated with the samples for 45 min at RT. In some cases CD4i
antibodies directly conjugated to horseradish peroxidase (see below)were
incubated with Env-expressing cells for 1 h at room temperature, remov-
ing the need to use an anti-Fc region antibody to develop the reaction. For
all conditions, cells were washed five times with blocking buffer and five
times with washing buffer. HRP enzyme activity was determined after the
addition of 30l per well of a 1:1 mix ofWestern Lightning oxidizing and
luminol reagents (PerkinElmer Life Sciences). Light emission was mea-
sured with an LB 941 TriStar luminometer (Berthold Technologies).
Horseradish peroxidase antibody conjugation. The HRP conjuga-
tion of aCD4i antibody (17b)was achieved as follows: 5mgof horseradish
peroxidase (HRP; Sigma) was diluted in freshly prepared 100 mM
NaHCO3 and incubated for 2 h in the dark at RT with agitation. At this
point, the antibody was added to the mixture together with Na2CO3 (10
mM final concentration) for 4 h in the dark at RT. The HRP-antibody
conjugate was stabilized with freshly preparedNaBH4 (132mM) for 1 h at
RT in the dark. Complexes were dialyzed against phosphate-buffered sa-
line (PBS) overnight at 4°C.
Cross-linking of envelope glycoproteins.Analysis of cross-linked tri-
meric envelope glycoproteins by cell-based ELISA was performed as de-
scribed above, with the exception that before the addition of blocking
buffer, cells were incubatedwith 5mMglutaraldehyde (GA) (Sigma) for 5
min at room temperature before the addition of 50mMglycine to quench
the unreacted GA.
Recombinant luciferase viruses.Recombinant viruses containing the
firefly luciferase genewere produced by calciumphosphate transfection of
293T cells with the HIV-1 proviral vector pNL4.3 Env Luc and the
pSVIIIenv plasmid expressing the wild-type or mutant HIV-1YU2 enve-
lope glycoproteins at a ratio of 2:1. Two days after transfection, the cell
supernatants were harvested; the reverse transcriptase activities of all vi-
ruses were measured as described previously (41). The virus-containing
supernatants were stored in aliquots at80°C.
Infection by single-round luciferase viruses.Cf2Th-CD4-CCR5 tar-
get cells were seeded at a density of 5 103 cells/well in 96-well luminom-
eter-compatible tissue culture plates (PerkinElmer) 24 h before infection.
Recombinant viruses (10,000 reverse transcriptase units) in a final volume
of 100l were then added to the target cells, followed by incubation for 48
h at 37°C; the medium was then removed from each well, and the cells
were lysed by the addition of 30 l of passive lysis buffer (Promega) and
three freeze-thaw cycles. An LB 941 TriStar luminometer (Berthold Tech-
nologies) was used to measure the luciferase activity of each well after the
addition of 100 l of luciferin buffer (15 mMMgSO4, 15 mM KPO4 [pH
7.8], 1 mMATP, and 1 mM dithiothreitol) and 50l of 1 mM D-luciferin
potassium salt (Prolume).
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Purification of recombinant HIV-1 gp120 glycoproteins. FreeStyle
293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitro-
gen) to a density of 1  106 cells/ml at 37°C with 8% CO2 with regular
agitation (125 rpm). Cells were transfected with a codon-optimized plas-
mid expressing His6-tagged wild-type or mutant HIV-1YU2 gp120 using
the 293Fectin reagent, as directed by the manufacturer (Invitrogen). One
week later, the cells were pelleted and discarded. The supernatants were
filtered (0.22-m-pore-size filter) (Corning), and the gp120 glycopro-
teins were purified by nickel affinity columns, as directed by the manu-
facturer (Invitrogen). The gp120 preparations were dialyzed against PBS
and stored in aliquots at 80°C. To assess purity, recombinant proteins
were loaded on SDS-PAGEpolyacrylamide gels and stainedwithCoomas-
sie blue.
SPR biosensor analysis. Surface plasmon resonance (SPR) biosensor
data were collected on a Biacore 3000 optical biosensor (General Electric).
Four-domain soluble CD4 (sCD4) and the 17b anti-gp120 monoclonal
antibody were immobilized onto separate flow cells within the same sen-
sor chip (CM5; GE) to a surface density of 500 response units (RU)
using standard amine coupling chemistry (42). The binding capacities of
CD4 and 17b surfaces were kept low to avoid mass transport effects and
steric hindrance. Flow cell 1 or 3 was left blank as a control for nonspecific
binding and refractive index changes. With the instrument operating in a
parallel sensingmode, soluble gp120was injected over flow cells 1 and 2 or
3 and 4 at different concentrations ranging from 100 to 750 nM at a flow
rate of 30 l/min for 3 min. This was followed by a 10-min dissociation
phase to allow an estimation of off-rates and binding affinities. Sensor
data were prepared for kinetic analysis by subtracting binding responses
collected from the blank reference surface. To examine the binding of the
17b antibody to gp120-CD4 complexes, a mixture of soluble gp120 and
sCD4 (molar ratio of 1:1) at concentrations ranging from 100 to 750 nM
was passed over the 17b chip. The association and dissociation phase data
were fitted simultaneously with BIAevalution, version 3.2, RC1 software
using a 1:1 Langmuir model of binding.
Statistical analysis.Comparison between groups was performed with
a Mann-Whitney rank sum test using SigmaPlot, version 6.0, software.
Datawere expressed asmeans	 standard deviations (SD), andP values of
0.05 were considered to be significant.
RESULTS
The HIV-1 gp120 layer 3 inner domain mutants. A seven-
stranded-sandwich in theHIV-1 gp120 inner domain serves as a
point of departure for the gp120 N and C termini, which roam
toward the viral membrane. The -sandwich and the gp120 ter-
minal strands have been implicated in the noncovalent association
of gp120with gp41 (3–5). Projecting from the-sandwich toward
the target cell membrane are three excursions that compose the
rest of the inner domain and, in two cases, transit into the neigh-
FIG 1 Structure of the inner domain of HIV-1 gp120 in the CD4-bound conformation. (A) The structure (27) of HIV-1HXBc2 gp120 (ribbon) complexed with
two-domain CD4 (red) is shown from the perspective of the Env trimer axis. The 20-21 strands of gp120 project from the outer domain and compose two of
the four strands of the bridging sheet. The other two strands of the bridging sheet are derived from the distal portion of layer 2. (B) A close-up view of the
conformation adopted by the inner domain layers 1, 2, and 3. (C) A close-up view of the interactions between layers 2 and 3. The side chain residues that were
altered in this and a previous study (3) are colored according to the gp120-trimer association index (red, association index of
0.5; green, association index of
0.7). (D) The side chain residues are colored according to CD4-Ig binding ability (red, relative CD4-Ig binding of 0.5; green, relative CD4-Ig binding of
0.5).
Role of gp120 Inner Domain Layer 3 on HIV-1 Entry
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boring gp120 domains (Fig. 1B). These excursions form three to-
pological layers (layers 1, 2, and 3) that have been proposed to
change conformation as gp120 undergoes the transition from the
unliganded to the CD4-bound state (3, 27).
In a recent study, we demonstrated the importance of layers 1
and 2 for the transition to the CD4-bound conformation (3). Our
mutagenesis study indicated that after the initial contact with
CD4, layer 1-layer 2 interactions strengthened gp120-CD4 bind-
ing by reducing the off-rate. This observation suggested that these
layers existed in a different conformation in the unliganded state
(3). However, the role of the gp120 inner domain layer 3, a highly
conserved element among HIV-1 isolates (Fig. 2), remains poorly
characterized. To investigate the role that layer 3 plays in Env
function in the unliganded and CD4-bound states, single amino
acid changes were introduced into the Env ofHIV-1YU2, a primary
virus directly cloned from anHIV-1-infected individual (43). The
changes were focused on layer 3 although a few alterations were
introduced into adjacent gp120 elements. The Env mutants were
evaluated with respect to the following properties: proteolytic
processing of the gp160 precursor, association of the gp120 and
gp41 subunits, CD4 binding (in monomeric and trimeric con-
text), functional ability to mediate cell-cell fusion and virus entry,
and the effect of soluble CD4 (sCD4) on virus infectivity (Table 1).
The conformation of gp120 in cell supernatants was assessed by
precipitation with a panel of monoclonal antibodies (MAbs)
that recognize conformation-dependent epitopes (Tables 1
and 2) (44, 45).
The ability ofmutant Env trimers to bind CD4.The effects of
the changes introduced into layer 3 of the inner domain on the
affinity of monomeric gp120 for CD4 were examined. The
amounts of radiolabeled wild-type (wt) and mutant gp120 in
the supernatants of Env-expressing 293T cells were normalized,
and equivalent amounts of gp120 were used for precipitation by
CD4-Ig. Alternatively, the ability of trimeric cell surface-expressed
Env variants to interact with CD4-Ig was also evaluated by cell-
based ELISA, as described in Materials and Methods. For cell-
based ELISAs, the cytoplasmic tail of the Env variants was trun-
cated to enhance cell surface expression; however, this did not
FIG 2 Sequences of HIV-1 and primate immunodeficiency virus Env. Pri-
mary sequence alignment of layer 3 gp120 residues from representative HIV-1
A (accession number ABB29387.1), HIV-1 B (accession number K03455),
HIV-1 C (AAB36507.1), HIV-1 D (P04581.1), HIV-1 F (ACR27173.1), HIV-1
G (ACO91925.1), HIV-1 H (AAF18394.1), HIV-1 J (ABR20452.1), HIV-1 K
(CAB59009.1), HIV-1 N (AAT08775.1), HIV-1 O (AAA99883.1), and HIV-1
P (ACY40659.1) viruses (A) and from primate immunodeficiency lineages
SIVcpz (accession number ABD19490.1), HIV-2 (AAC95347.1), SIVmac/smm
(AAA47637.1), SIVtan (AAC57057.1), SIVagm (AAA91919.1), and SIVsyk
(AAA74712.1) (4, 5) (B). Secondary structure elements are shown above the
sequences (4, 5). The shading highlights residues that are conserved.
TABLE 1 Phenotypes of HIV-1 gp120 mutantsa
Envelope
glycoprotein
Processing
index
Association
index
CD4-Ig
binding
Cell-cell
fusion
Relative
infectivity
sCD4 IC50
(nM)b
Wild-type YU2 1.00 1.00 1.00 1.00 1.00 60
T248A 0.40 0.94 0.30 0.98 0.98 50
H249A 0.67 1.18 0.49 1.32 0.68 100
R252A 0.66 0.65 0.62 1.04 1.05 100
P253A 0.85 0.82 1.00 1.48 0.62 100
V254A 0.66 0.51 0.75 1.22 1.02 160
R476A 1.23 0.90 0.31 1.48 1.18 160
R476E 0.73 0.95 0.14 1.52 0.53 100
D477A 0.95 0.95 0.60 1.40 0.43 140
N478A 0.77 0.75 0.44 1.24 0.36 200
W479A 0.91 0.12 0.23 0.97 0.06 180
R480A 0.90 1.60 0.86 0.91 0.77 70
S481A 1.25 0.74 1.36 1.17 0.78 80
E482A 0.63 0.94 0.79 1.17 0.52 40
L483A 0.80 0.91 0.77 1.36 0.47 60
a The phenotypes of the wt and mutant Env glycoproteins were determined as described in Materials and Methods. All mutated residues are located in layer 3. Data represent the
mean values derived from at least three experiments. Less than 20% deviation from the mean value was typically observed.
b IC50, 50% inhibitory concentration.
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affect precursor processing or gp120-gp41 association (Table 3).
Finally, all cytoplasmic tail-deleted Env variants were tested for
their ability to interact with the PG9 and PG16 antibodies, which
preferentially bind trimeric Env (46).
Five layer 3 changes decreased the efficiency of mutant gp120
interaction with CD4. A strong correlation between CD4-Ig bind-
ing by monomeric gp120 and trimeric Env variants was observed
(Fig. 3A) although some mutants exhibited a more pronounced
decrease in the context of monomeric gp120. Nevertheless, the
T248A, H249A, R476A, N478A, and W479A mutants exhibited
decreased CD4-Ig binding in both assays (Fig. 3A and B; Tables 1
and Table 3). The observed decreases in CD4 binding weremainly
due to decreased on-rates compared with that of wt gp120 (Table
4). Thus, gp120 mutants with alterations in layer 3 fail to engage
CD4 efficiently. The five layer 3 residues implicated in CD4 bind-
ing are located in the 8 strand and 5 helix of the CD4-bound
gp120. A network of interactions involving some residues of the
8-5 region in layer 3may contribute to CD4 binding by helping
to shape the nearby Phe43 cavity that directly contacts CD4 (26,
47, 48). Similarly, several layer 3 variants resulted in decreased
recognition by antibodies (b12 and VRC01) directed against the
CD4-binding site of gp120 (Tables 2 and 3). In summary,multiple
residues in layer 3 of the gp120 inner domain that do not directly
contact CD4 nonetheless contribute to the affinity of the gp120-
CD4 interaction.
Effect of filling the Phe43 cavity on the phenotypes of inner
domainmutants. Serine 375 flanks the Phe43 cavity; substitution
of a tryptophan residue for serine 375 fills the Phe43 cavity with
the indole ring (49). As a result, the S375Wmutant favors confor-
mation(s) closer to that of the CD4-bound state (50). To deter-
mine whether such a change in gp120 conformation would influ-
ence the phenotypes of the inner domain mutants, we introduced
the S375W change into some of the gp120 variants described
above. Remarkably, the S375W change completely restored the
CD4-binding abilities of gp120 mutants with alterations in R252,
V254, D477, N478, andW479 (Fig. 3B). The compensatory effect
of S375Wwas observed in the context of monomeric and trimeric
Env, as shown by cell-based ELISA (Fig. 3C and Table 3). In the
context of monomeric gp120, introduction of the S375W change
restored CD4 binding affinity by increasing the on-rate and de-
creasing the off-rate (Table 4). Thus, some changes in layer 3 dis-
rupt the conformational transition of gp120 from the unliganded
state to the CD4-bound state, and these detrimental effects on
CD4 binding can be compensated by filling the Phe43 cavity with
a hydrophobic tryptophan side chain.
Recognition of mutants by ligands that prefer the CD4-
bound conformation. We examined the binding of a panel of
layer 3 gp120 mutants to CD4-induced (CD4i) Abs (17b and
TABLE 2 Recognition of HIV-1YU2 gp120 variants by monoclonal
antibodiesa
Envelope
glycoprotein
Binding affinity for:b
17b 412d b12 VRC01 C11 2G12
Wild-type YU2 1.00 1.00 1.00 1.00 1.00 1.00
T248A 0.09 0.12 0.20 0.17 0.14 0.51
H249A 0.36 0.49 0.47 0.39 0.37 0.64
R252A 0.27 0.19 0.86 0.64 0.54 0.78
P253A 0.26 0.29 0.77 0.71 0.63 0.93
V254A 0.48 0.55 1.16 0.99 1.07 1.12
R476A 0.19 0.30 0.75 0.43 0.59 0.84
R476E 0.11 0.18 0.32 0.21 0.22 0.70
D477A 0.30 0.57 0.31 0.48 0.58 0.87
N478A 0.14 0.23 1.08 0.51 0.50 0.84
W479A 0.02 0.04 0.53 0.29 0.35 0.60
R480A 0.50 0.84 1.21 0.75 0.81 1.03
S481A 0.83 1.35 1.32 1.32 1.43 1.06
E482A 0.53 1.18 0.89 0.60 0.81 0.98
L483A 0.32 0.40 1.51 0.71 0.96 1.33
a 293T cells transiently expressing the indicated HIV-1 Env glycoproteins were
radiolabeled, and the supernatants were precipitated with a mixture of sera from HIV-
1-infected individuals. The precipitates were analyzed on nonreducing and reducing
SDS-polyacrylamide gels, as reported by Finzi et al. (45). All mutated residues are
located in layer 3.
b Comparable amounts of radiolabeled wt and mutant gp120 glycoproteins were
incubated with a 13 nM concentration of the indicated antibody for 1 h at 37°C.
Precipitates were analyzed by SDS-PAGE and autoradiography/densitometry. The
amount of mutant gp120 precipitated by the monoclonal antibody, normalized to the
amount of gp120 precipitated by a mixture of sera from HIV-1-infected individuals, is
reported relative to the value obtained for wt gp120. The results shown represent the
average of at least two independent experiments.
TABLE 3 Characterization of ligand binding to selected HIV-1YU2 gp120 variants by cell-based ELISA
a
Envelope
glycoprotein
Processing
index
Association
index
Binding affinity for:
CD4-Ig 17b 17b sCD4 VRC01 PG9 PG16
Wild-type YU2 1.00 1.00 1.00 1.00 2.77 1.00 1.00 1.00
T248A 0.32 0.75 0.72 0.92 1.70 0.72 0.45 0.44
H249A 0.38 1.01 0.83 1.09 2.15 0.81 0.68 0.35
R252A 0.79 0.75 0.81 0.48 2.53 0.91 1.00 0.62
P253A 0.61 0.56 0.67 0.85 1.69 0.75 0.63 0.45
V254A 1.03 0.73 0.70 0.68 1.70 0.86 1.06 0.49
R476A 0.83 0.85 0.59 0.95 1.72 0.76 0.60 0.59
D477A 0.59 0.81 0.76 1.06 2.31 0.65 0.75 0.78
N478A 0.75 0.55 0.64 0.33 1.41 0.56 0.38 0.55
W479A 0.62 0.19 0.64 0.35 1.05 0.38 0.08 0.16
R480A 0.50 0.92 1.15 0.88 2.51 0.92 0.48 0.45
S481A 0.85 1.02 1.17 0.89 2.58 0.72 0.32 0.43
E482A 0.59 1.10 0.79 0.79 1.78 0.81 0.50 0.53
L483A 0.58 0.44 0.64 0.44 1.18 0.45 0.57 0.60
a The phenotypes of the wt and mutant Env glycoproteins were determined as described in Materials and Methods. All mutated residues are located in layer 3. Data represent the
mean values derived from at least three experiments. Less than 20% deviation from the mean value was typically observed.
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412d) that preferentially recognize the CD4-bound conformation
(51, 52). These ligands bind overlapping, conserved regions on
gp120 (26, 53).
In themonomeric context and in the absence of sCD4, all layer
3 changes tested, with the exception of S481A, moderately
(H249A, V254A, R480A, and E482A) or substantially (T248A,
R252A, P253A, R476A, R476E, D477A, N478A, W479A, and
L483A) decreased CD4i binding (17b and 412d) compared with
the binding of wt gp120 (Fig. 4A and B; Table 2). As expected (50),
the S375Wchange that fills the Phe43 cavity increased 17b binding
of wt gp120 in the absence of sCD4. Importantly, with the excep-
tion ofW479A, the S375W change restored 17b binding towt levels
for the rest of the layer 3 variants tested (Fig. 4C and Table 4).More-
over, addition of sCD4 also reestablished the ability of layer 3
mutants, including W479A, to interact efficiently with 17b (Fig.
4D and Table 4). Thus, alteration of layer 3 residues in the gp120
inner domain decreases CD4i antibody binding to monomeric
gp120 in amanner that can be compensated by the S375W change
or by sCD4 binding. These results suggest that the layer 3 gp120
residues do not directly interact with the 17b antibody, consistent
with the crystal structure of the gp120 core-CD4-17b complex
(26, 53).
Reductions mainly in on-rates, with some acceleration of off-
rates, contributed to the decreased affinity of layer 3 variants for
17b (Table 4). These results are consistent with a model in which
these mutants do not spontaneously sample the conformation
recognized by the 17b antibody, and when they do, they have
difficulty in retaining the antibody as efficiently as wt gp120. Thus,
layer 3 in the inner domain contributes to the ability of HIV-1
gp120 to assume the conformation preferred by CD4i Abs.
Similar observations on decreased CD4i interaction, albeit less
pronounced, were made when layer 3 variants were expressed in
the trimeric context and assessed for CD4i binding by cell-based
ELISA (Fig. 5A). Significantly, 17b recognition of most Env mu-
tants in the trimeric context could be restored by addition of sCD4
(Fig. 5A), as was seen for the monomeric gp120 variants. As de-
scribed above, interaction with sCD4 forces the Env trimers to
assume the CD4-bound conformation; in our assay this is mea-
sured by a 2- to 3-fold enhancement of 17b recognition, upon
sCD4 addition, for the wt Env (Fig. 5A and B). For Envs expressed
on the cell surface, introduction of the S375Wchange restored 17b
binding to wt levels for the majority of layer 3 mutants, with the
exception of W479A (Fig. 5B). Association with sCD4 further en-
hanced 17b binding of all S375W-containing layer 3 variants (in-
cluding W479A/S375W).
To investigate further the contribution of layer 3 to the confor-
mation sampled by HIV-1 Env trimers in the unliganded state, we
conformationally fixed cell surface Envs prior to probing with
specific ligands in the cell-based ELISA (28, 54). In this procedure,
glutaraldehyde (GA) cross-linking is used to fix the conformation
of Env, and then the relative occupancy of gp120 conformations is
assessed by quantifying the binding of ligands with different re-
quirements for specific gp120 conformations. GA cross-links
lysine residues and thereby fixes the conformation of the protein
component of the envelope glycoproteins (55). Cells were left un-
treated or cross-linked (5 mM GA) and incubated with a poly-
clonal mixture of sera (PS) from HIV-1-infected individuals,
CD4-Ig, or monoclonal Abs that recognize different conforma-
tions of the HIV-1 Env trimers. The polyclonal mixture of sera
recognizes multiple conformations sampled by HIV-1 Env trim-
ers; therefore, the signal obtained with PS can be used to normal-
ize mutant Env expression levels at the cell surface (1). The CD4i
17b antibody recognizes gp120 epitopes that overlap the chemo-
kine receptor-binding site and that are normally formed and ex-
posed after CD4 binding (51). Therefore, it recognizes conforma-
tions closer to the CD4-bound state. In contrast, the CD4-binding
site VRC01 antibody recognizes multiple gp120 conformations
(56), and the inner-domain-recognizing antibody A32 has only
modest conformational preference (28). We also included two
HIV-1 Env trimer variants known to preferentially sample distinct
unliganded conformations: the S375W change favors the sponta-
FIG 3 Recognition of layer 3 gp120 variants by CD4. The effects of alterations
in layer 3 on gp120 recognition by CD4-Ig were examined for monomeric
soluble gp120 by immunoprecipitation or for cellular-expressed trimeric Env
by cell-based ELISA (A). In both contexts, the gp120 variants were normalized
by patient serum (PS) and to the signal obtained for their wt counterparts. The
effect of filling the Phe43 cavity with a tryptophan (S375W) on layer 3 variants
was analyzed by immunoprecipitation (B) or by cell-based-ELISA (C) with
CD4-Ig. Data shown represent themeans	 standard errors of themeans of at
least two independent experiments. *, P
 0.05 by aMann-Whitney rank sum
test. Differences with P values of0.05 were not considered significant (ns).
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neous sampling of a CD4-bound-like conformation (50), whereas
a change in layer 1, H66A, has been shown to block the transition
to the CD4-bound conformation (3, 57, 58). Accordingly, the ra-
tio of cross-linked to untreated HIV-1 Env trimers recognized by
17b was enhanced for the S375W mutant and dramatically re-
duced for the H66A mutant, compared to this ratio for wt HIV-1
Env trimers. Similar to the H66A mutant, the majority of layer 3
variants exhibited greater-than-wt decreases in 17b recognition
TABLE 4 Characterization of ligand binding to selected HIV-1YU2 gp120 mutants by surface plasmon resonance
gp120 protein
Binding affinity for:a
sCD4 17b 17b sCD4
On-rate
(M1 s1)
Off-rate
(s1)
KD (M [fold
change])
On-rate
(M1 s1)
Off-rate
(s1)
KD (M [fold
change])
On-rate
(M1 s1)
Off-rate
(s1)
KD (M [fold
change])
Wild type 2.23 104 2.21 104 9.90 109 (1.00) 5.54 104 5.98 105 1.08 109 (1.00) 4.20 104 5.77 105 1.38 109 (1.00)
T248A 7.74103 3.59 104 4.64 108 (4.69) 6.61 104 6.81 103 1.03 107 (95.54) 1.88 104 1.32 104 6.99 109 (5.08)
V254A 1.40 104 2.88 104 2.05 108 (2.08) 1.08 104 1.11 104 1.02 108 (9.49) 3.08 104 8.48 105 2.75 109 (2.00)
R476A 1.07 104 2.61 104 2.45 108 (2.46) 4.40 103 5.75 105 1.31 108 (12.14) 2.70 104 5.19 105 1.92 109 (1.40)
D477A No binding 9.62 103 5.14 105 5.34 109 (4.96) 9.30 103 8.90 105 9.57 109 (6.96)
N478A 4.84 103 3.32 104 6.86 108 (6.93) 2.99 103 1.88 104 6.29 108 (58.33) 2.13 104 6.93 105 3.26 109 (2.37)
W479A No binding No binding 7.42 103 8.56 105 1.15 108 (8.39)
S375W 1.43 104 1.94 106 1.33 1010 (0.01) 7.67 104 4.96 105 6.47 1010 (0.60) 2.94 104 6.90 105 2.35 109 (1.70)
V254A S375W 4.37 104 4.97 105 1.14 109 (0.12) 6.94 104 5.19 105 7.47 1010 (0.69) 3.83 104 7.81 105 2.04 109 (1.48)
R476A S375W 2.88 104 5.64 105 1.96 109 (0.19) 5.11 104 4.84 105 9.47 1010 (0.88) 2.64 104 8.49 105 3.21 109 (2.34)
D477A S375W 5.67 104 4.39 105 7.74 1010 (0.08) 5.78 104 4.10 105 7.11 1010 (0.66) 2.80 104 7.27 105 2.60 109 (1.89)
W479A S375W 1.55 104 4.00 104 2.59 108 (2.61) 4.29 104 3.13 104 7.29 109 (6.76) 1.29 104 7.24 105 5.62 109 (4.08)
a The gp120-reactive ligand (sCD4 or 17b) was immobilized directly onto a CM5 sensor chip and the binding of the indicated gp120 protein was evaluated as described in Materials
and Methods. No binding, detected signal below accurate analysis of kinetics parameters; KD, equilibrium dissociation constant.
FIG 4 Recognition of soluble gp120 variants by CD4i monoclonal antibodies. Comparable amounts of radiolabeled wt and mutant gp120 were incubated with
13 nm of 17b (A) or 412d (B) CD4i Abs for 1 h at 37°C. Alternatively, the effect of filling the Phe43 cavity with a tryptophan (S375W) (C) or of adding sCD4 (D)
to layer 3 on 17b recognition was assessed by immunoprecipitation. gp120 variants were normalized by PS and to the signal obtained for their wt counterparts.
Precipitates were analyzed by SDS-PAGE and densitometry. Incubation with sCD4 increased the binding of wt gp120 to 17b 1.5-fold. Data shown represent the
means	 standard errors of themeans of at least two independent experiments. *, P
 0.05 by aMann-Whitney rank sum test. Differences with P values of0.05
were not considered significant (ns).
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FIG 5 Recognition of cellular-expressed trimeric HIV-1 Env variants by a CD4i monoclonal antibody. The effects of alterations in layer 3 on gp120 recognition
by 17b, a CD4i antibody, were examined in the absence or presence of CD4 (13 nM CD4-Ig) by cell-based ELISA (A). To avoid recognition of the Ig portion of
the CD4-Ig fusion protein by a secondary antibody, 17b was directly conjugated to HRP, as described in Materials and Methods. The effect of filling the Phe43
cavity with a tryptophan (S375W) on layer 3 variants was also analyzed by cell-based-ELISA (B). HIV-1 Env variants were normalized by PS and to the signal
obtained for the wt. The S375W mutant, known to interact better with CD4i Abs (50), was introduced for comparison. Data shown represent the means 	
standard errors of the means of at least four independent experiments. (C and D) Conformational fixation followed by ligand selection. The ratio of ligand
binding to cross-linked versus untreated HIV-1 Env trimer is shown for wt and layer 3 variants without (C) or with (D) filling of the Phe43 cavity. Signals were
normalized to those obtained for the wt. Data shown are representative of at least three independent experiments performed in duplicate. *, P 
 0.05 by a
Mann-Whitney rank sum test. Differences with P values of0.05 were not considered significant (ns).
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upon cross-linking, with the more pronounced phenotypes ob-
served for the T248A, R252A, P253A, N478A,W479A, and L483A
mutants (Fig. 5C). VRC01 andA32 recognized the cross-linkedwt
and layer 3 variants similarly. Importantly, filling the Phe43 cavity
restored 17b recognition to wt levels for all the layer 3 variants
tested, with the exception of W479A (Fig. 5D). Altogether, these
data support the hypothesis that layer 3 integrity is important for
the spontaneous sampling of the CD4-bound conformation by
HIV-1 Env trimers.
Proteolytic processing and subunit association of the Env
glycoprotein mutants. Proteolytic processing of the gp160 pre-
cursor and association of the gp120 and gp41 subunits of each
mutant Env trimer were evaluated. All of the mutants were ex-
pressed efficiently, and only mutant T248A exhibited a marked
decrease in proteolytic processing of the gp160 Env precursor (Ta-
ble 1), perhaps due to its proximity to cysteine 247. In striking
contrast to the major contribution of inner domain layer 1 and
layer 2 residues to subunit association within the Env trimer (3),
changes in only one layer 3 residue (W479) significantly dis-
rupted the noncovalent association of gp120 with the Env
trimer (Table 1). Apparently, layer 3 as a whole is not directly
responsible for gp120 association with the unliganded Env glyco-
protein trimer. ResidueW479 locates at the center of a hydropho-
bic interface between layers 2 and 3 (Fig. 1C and D). Changes in
Trp479 might affect trimer stability through effects on layer
2-layer 3 association, which could indirectly affect gp120-trimer
association by altering either the gp120-trimer association do-
main or the gp120-gp41 interface. Consistent with the relevance
of layer 2-layer 3 interaction to this phenotype, M104 in layer 2,
which contacts W479 in the CD4-bound conformation (26), has
been previously shown to be involved in gp120-gp41 association
(3). Indeed, substitution of a tryptophan residue for methionine
104 enhanced gp120-trimer association on its own; more impor-
tantly, the M104W change was sufficient to restore gp120-trimer
association of W479A to a wt level (Fig. 6). This observation sup-
ports the hypothesis that the phenotypic effect of the W479A
change on gp120-trimer association results from a disruption of
an interaction between layers 2 and 3.
In the unliganded state, layer 2-layer 3 interactions could po-
tentially influence the spatial relationship of the gp120 inner and
outer domains. Elements of both domains (V1/V2 in the inner
domain and V3 in the outer domain) contribute to the trimer
association domain (TAD) of gp120 (35). Unlike the well-con-
served gp120 regions that directly interact with gp41, changes in
the gp120 TAD result in more dramatic phenotypes in R5 HIV-1
Envs than in R5 or R5X4 HIV-1 Envs (59). To examine whether
W479A exhibited this property, we introduced this change into
Envs derived from the R5 HIV-1ADA, the dual-tropic (R5X4)
HIV-189.6 (60, 61), and the CXCR4-using (X4) HIV-1HXBc2 (62)
viruses. TheW479A change resulted inmassive shedding of gp120
in the two R5 strains tested (YU2 and ADA) and less extensive
shedding in the X4 (HXBc2) and R5X4 (89.6) Envs (Fig. 6B and
C), as predicted for an effect mediated through the gp120 TAD. In
this sense, theW479A change almost completely abrogated recog-
nition of trimeric Envs by PG9/PG16 antibodies (Table 3) that
recognize epitopes present in conserved portions of the gp120
variable regions (46).
Function of the mutant HIV-1 Env trimers. The mutant
HIV-1 Env trimers were assessed for the ability tomediate cell-cell
fusion and to support virus entry into cells expressing CD4 and
CCR5. In both assays, most of the mutant Env trimers exhibited
detectable activity (Table 1). The mutant W479A, with the lowest
gp120-gp41 association index, also exhibited the lowest infectiv-
ity. However, it mediated cell-cell fusion much more efficiently
than cell-free virus infection. This phenotype has previously been
observed for alterations in the inner domain layers 1 and 2 and the
-sandwich that affect gp120-trimer association (3, 5). Because
the time betweenEnv synthesis and engagement of the target cell is
much longer in the virion infectivity assay than in the cell-cell
FIG 6 Inner domain residues important for gp120-trimer association. Cell
lysates and supernatants (SN) of 35S-labeled cells transiently expressing the
HIV-1YU2 (A), HIV-1HxBc2, HIV-189.6, and HIV-1ADA (B) and indicated mu-
tant envelope glycoproteins were precipitated with serum from HIV-1-in-
fected patients. The precipitated proteins were loaded onto SDS-PAGE poly-
acrylamide gels and analyzed by autoradiography and densitometry. (C) A
quantification of the data shown in panel B. The association index is ameasure
of the ability of the mutant gp120 molecule to remain associated with the
envelope glycoprotein complex on the expressing cell relative to that of the
wild-type envelope glycoproteins. The association index was calculated as de-
scribed in Materials and Methods. Data shown represent the average	 stan-
dard deviation of at least two independent experiments.
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fusion assay, the former assay is more sensitive to decreases in the
stability of gp120-trimer association.
Sensitivity of the mutant viruses to neutralization by sCD4.
Changes in CD4-binding affinity can result in altered HIV-1 sen-
sitivity to sCD4-mediated neutralization (3, 63). Several viruses
bearing Env trimers with alterations in layer 3 (V254A, R476A,
D477A, N478A, and W479A) were more resistant to sCD4 than
viruses with wt Env trimers (Fig. 7A and Table 1). The introduc-
tion of the S375W change, which fills the Phe43 cavity (49, 50),
into these sCD4-resistant mutant Env trimers resulted in viruses
that were neutralized very efficiently by sCD4. Indeed, they were
neutralized to the same extent as a virus with the S375W change
alone, known to be neutralized more efficiently by sCD4 than
viruses with the wt Env (3, 50) (Fig. 7 B). Thus, changes in layer 3
of the gp120 inner domain specifically affect sCD4 binding and
virus neutralization.
A prominent consequence of sCD4 binding is the shedding of
gp120 from the Env trimer (3, 64, 65).Mutants R476A andN478A
exhibited degrees of sCD4-induced gp120 shedding proportional
to their degrees of sCD4-mediated neutralization. Indeed, R476A,
which is partially resistant to sCD4 neutralization, showed a slight
decrease in shedding upon sCD4 addition, whereas N478A
(highly resistant to sCD4-mediated neutralization) was com-
pletely resistant to sCD4-induced shedding (Fig. 7C). Impor-
tantly, the S375W change restored the efficiency of sCD4-induced
gp120 shedding in the R476A and N478A mutant Env trimers to
levels comparable to the wt Env level (Fig. 7D). Thus, for this
group of layer 3 mutants, sCD4 binding to gp120 and sCD4 in-
duction of gp120 shedding correlate, in agreementwith previously
observed phenotypes of layer 1 and layer 2 mutants involved in
modulating CD4 binding indirectly (3).
Soluble CD4 is also known to induce a transiently activated
state in the HIV-1 Env trimers (39). We previously reported that
layer 1 and layer 2 played a role in this process as changes in the
interface between these layers resulted in a long-lived activated
state (3). However, none of our layer 3 mutants were activated by
sCD4 and were therefore unable to infect CD4-negative, CCR5-
expressing cells when incubated with different concentrations of
sCD4 (not shown).
DISCUSSION
Current structural and functional studies have led to the hypoth-
esis that, in the process ofmoving from the unliganded state to the
CD4-bound state, the gp120 inner domain undergoes layered
movement, whereas the outer domainmaintains its conformation
(35). Here, we extended our comprehension of the network of
interactions involving the gp120 inner domain that modulate
FIG 7 Sensitivity of HIV-1 Env gp120 variants to soluble CD4. (A and B) Recombinant HIV-1 expressing luciferase and bearing wt ormutant HIV-1 Env trimer
were normalized by reverse transcriptase activity. Equal amounts of viruses were incubated with serial dilutions of sCD4 at 37°C for 1 h prior to infection of
Cf2Th-CD4/CCR5 cells. Infectivity at each dilution of sCD4 tested is shown as the percentage of infection without sCD4 for each particular mutant. Quadru-
plicate sampleswere analyzed; data shown are representative of values obtained in at least three independent experiments. (C andD)The sCD4-induced shedding
of gp120 fromHIV-1 Env expressed on the cell surface. Transfected 293T cells weremetabolically labeled with [35S]methionine-cysteine for 16 h with increasing
concentrations of sCD4 (0 to 400 nM). Cell lysates were precipitated with PS. Precipitates were analyzed by SDS-PAGE and densitometry. Data shown are
representative of values obtained in at least two independent experiments.
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gp120 association with the Env trimer, CD4 binding affinity, and
susceptibility to inactivation by sCD4 (3).
Before engaging the CD4 receptor, gp120 must maintain its
noncovalent associationwith gp41 and prevent gp41 fromprema-
turely undergoing transitions to lower-energy conformations. In
addition to the role of the inner domain -sandwich and the N
and C termini of gp120 in mediating gp120-gp41 association (4,
5), layers 1 and 2 of the gp120 inner domain are also involved in
maintaining the association of gp120 with the Env trimer (3). An
additional element of the gp120 inner domain, layer 3, apparently
contributes to the association of gp120 with the unliganded Env
trimer, likely through an indirect mechanism. Indeed, various
layer 2 residues, including M104, were previously shown to be
important for gp120-trimer association (3). Interestingly, the only
layer 3 residue implicated in trimer stability, W479, directly con-
tacts M104 in the CD4-bound conformation (Fig. 1C). Introduc-
tion of a compensatory mutation in layer 2 (M104W) (Fig. 6) is
sufficient to restore gp120-trimer association to the layer 3
W479A mutant. This observation supports a model in which the
effect of the W479A change on trimer stability is mediated by
modulating layer 2-layer 3 interactions required for proper
gp120-trimer association. Shifts between the inner domain and
outer domain that occur as a result of the W479A change in the
layer 2-layer 3 interface might affect the orientation of V3 (which
has an outer-domain base) and V1/V2 (with an inner-domain
base). These effects on the V3 and V1/V2 relationship could affect
the conformation of the trimer association domain (TAD), which
comprises the V1, V2, and V3 variable regions and appears to be a
key element in maintaining interactions among the gp120 sub-
units in the Env trimer (35). Consistent with this model, the
W479A change resulted in greater gp120 shedding in the context
of R5 HIV-1 isolates (thought to represent a more “compact”
conformation) than in X4 or R5X4 isolates; Envs of the latter
viruses are thought to have an open conformation where the con-
tribution of the TAD to trimer stability might be less important
(31, 35, 59, 66). Previous work has demonstrated a more promi-
nent role of V3 in trimer stability for primary R5 isolates than for
X4 or R5X4 isolates (59).
Conformational metastability in the unliganded HIV-1 Env
trimer (28, 54, 67, 68) is expected to provide advantages for im-
mune evasion (69, 70). By mechanisms that are not yet well un-
derstood, the gp120 TAD can apparently modulate this property.
Removing the gp120 TAD, composed of the V1, V2, and V3 vari-
able regions, allows the gp120 core to assume the CD4-bound
conformation (28). In the transition from the unliganded state to
the CD4-bound state, the inner domain of gp120, but not the
outer domain, experiences dramatic conformational rearrange-
ments (35). Located at the interface between the inner domain and
outer domain, layer 3 is structurally expected to play a pivot-like
role in the layered allosteric changes in the inner domain. Changes
in layer 3 apparently decrease the spontaneous sampling of the
CD4-bound conformation by HIV-1 gp120, in several instances
lowering the on-rate and binding affinity of CD4i Abs and dra-
matically decreasing the recognition of cross-linked, cell surface-
expressed Env trimers by CD4i Abs.
In contrast to what was observed for alteration of the layer 1
and layer 2 interaction, where decreased CD4 binding was mainly
due to an accelerated off-rate (3), the layer 3 variants tested by SPR
in this study (T248A, V254A, R476A, D477A, N478A, and
W479A) mainly affected CD4 binding by decreasing the initial
contact with CD4 (on-rate). The integrity of layer 3 thus appears
to be necessary for the optimal presentation and exposure of the
CD4-binding site. The S375W change, which fills the Phe43 cav-
ity, completely compensates for the inability of most layer 3 mu-
tants to initiate CD4 binding. Furthermore, the S375W change is
sufficient to allow spontaneous sampling of the conformation re-
quired for efficient recognition by CD4i Abs, even after cross-
linking. Thus, in addition to layers 1 and 2 in the inner domain,
layer 3 contributes to the ability of gp120 to make the transition
from the unliganded to the CD4-bound state.
Alteration of some gp120 residues in layer 3 (V254A, R476A,
D477A, N478A, and W479A) resulted in increased resistance to
neutralization by sCD4. Differences in the affinity of monomeric
gp120 or trimeric Env for CD4 likely contribute to the sCD4 re-
sistance of these mutants, as has been observed for other HIV-1
Env variants with decreases in CD4 binding (3, 63). Consistent
with this, the S375W change restores the CD4-binding affinity of
all these mutants and reverts the phenotypes of resistance to both
sCD4 neutralization and sCD4 induction of gp120 shedding.
The involvement of layer 3 residues in CD4 andCD4i antibody
binding and the particular influence ofW479 in gp120 association
with the Env trimer suggest a model for the triggering of the con-
formational changes required for HIV-1 entry. According to this
model (Fig. 8), in the unliganded state, layer 3 helps expose the
FIG 8 Model for the role of layer 3 in HIV-1 Env trimer stability and CD4 bind-
ing. The image on the top left depicts the unligandedHIV-1 Env trimer, with two
gp120 subunits and two gp41 subunits visible from the perspective shown. The
gp120 subunit on the right is subdivided into the outer domain (OD), inner do-
main (-sandwich [red] and layers 1, 2, and 3), and the TAD (V1/V2, and V3
regions) (35). The initial site ofCD4binding is circled in black, and the location of
the Phe43 cavity is shown by an asterisk. Layer 3 modulates the interaction of the
outer domain and layer 2 in the inner domain. The upper right image shows the
consequences of changes in Trp479, which is located in layer 3, in the gp120 inter-
domain interface. Changes in Trp479 significantly disrupt the relationship of the
inner and outer domains. Because the V1/V2 and V3 regions are anchored in
the inner and outer domains, respectively, the gp120 TAD, which comprises the
V1/V2 andV3 regions, is disrupted. Thus, changes in Trp479 lead to trimer insta-
bility and gp120 shedding. The images in the bottomrow illustrate the phenotypic
consequences of changes in layer 3 that are less disruptive than the alteration of
Trp479. These more subtle changes in layer 3 cause local alterations of gp120
conformation around the Phe-43 cavity that affect CD4 binding, with effects on
both on-rate and off-rate (bottompanels). Themore subtle changes in layer 3 can
be compensated by the S375Wchange,whichfills the Phe43 cavitywith the indole
ring of tryptophan.
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initial site of contact with CD4 and helps to maintain a relation-
ship between the gp120 inner and outer domains that is necessary
for TAD-mediated gp120 association with the Env trimer. Upon
CD4 binding, layer 3 interacts with layer 2, contributing to the
rearrangement of the gp120 inner domain that slows the off-rate
of CD4. CD4 binding also leads to TAD conformational changes
contributing to the “opening” of the Env trimer at its apex.
Importantly, the residues in layer 3 implicated in the CD4-
induced conformational transition are well conserved among the
HIV-1 lineage (Fig. 2A). Of interest, some residues (such as
W479) are also conserved among the HIV-2/simian immunode-
ficiency virus SIVsm lineage although differences between the
HIV-1/SIVcpz andHIV-2/SIVsm lineages are evident (Fig. 2B). For
example, residue 375 is naturally a tryptophan in theHIV-2/SIVsm
viruses (71); in HIV-1, substitution of tryptophan for serine 375
fills the Phe43 cavity and diminishes the impact of alterations in
layers 1, 2, and 3 on CD4 and CD4i antibody binding. Thus, while
both immunodeficiency virus lineages preserve the potential to
form a network of inner domain interactions involving layers 1, 2,
and 3, some lineage-specific differences exist. Indeed, subtlemod-
ifications in the organization of layers 1 and 2 of the inner domain
of HIV-1 and SIV gp120 were recently reported to modulate
trimer stability and CD4 binding differentially (72). Therefore,
fine differences in the regulation of this network of inner domain
interactions might help explain how these Env trimers adapted to
their respective hosts; additional work is required to assess the role
of layer 3 in the HIV-2/SIVsm lineage.Work aimed at understand-
ing the underlying molecular mechanism of the transition from
the unbound to the CD4-bound conformation may greatly expe-
dite the development of interventions.
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